VIM and prostate carcinoma: With regard to prostate cancer targeting, we were able to show uptake of CPMV nanoparticles by the prostate cancer cell lines and that HMEC-1 cells (surrogate cells for human vascular endothelium) did not bind the SC5 vimentin specific mAb.